{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:14:11Z","timestamp":1763036051096},"reference-count":38,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.vaccine.2005.03.022","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T11:10:07Z","timestamp":1113822607000},"page":"4128-4135","source":"Crossref","is-referenced-by-count":22,"title":["Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways"],"prefix":"10.1016","volume":"23","author":[{"given":"K.","family":"McEvers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Elrefaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2005.03.022_bib1","series-title":"Sourcebook of bacterial protein toxins","first-page":"277","article-title":"The anthrax toxin complex","author":"Leppla","year":"1991"},{"key":"10.1016\/j.vaccine.2005.03.022_bib2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1099\/00221287-29-3-517","article-title":"Purification of the third factor of anthrax toxin","volume":"29","author":"Smith","year":"1962","journal-title":"J Gen Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2005.03.022_bib3","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1073\/pnas.79.10.3162","article-title":"Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells","volume":"79","author":"Leppla","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2005.03.022_bib4","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1073\/pnas.0431098100","article-title":"Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor","volume":"100","author":"Scobie","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6860","key":"10.1016\/j.vaccine.2005.03.022_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"issue":"32","key":"10.1016\/j.vaccine.2005.03.022_bib6","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.1016\/S0021-9258(17)32036-7","article-title":"Anthrax protective antigen forms oligomers during intoxication of mammalian cells","volume":"269","author":"Milne","year":"1994","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.vaccine.2005.03.022_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2958.1995.tb02375.x","article-title":"Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus","volume":"15","author":"Milne","year":"1995","journal-title":"Mol Microbiol"},{"issue":"6619","key":"10.1016\/j.vaccine.2005.03.022_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/385833a0","article-title":"Crystal structure of the anthrax toxin protective antigen","volume":"385","author":"Petosa","year":"1997","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.022_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.1462-5822.2000.00057.x","article-title":"Translocation of Bacillus anthracis lethal and oedema factors across endosome membranes","volume":"2","author":"Guidi-Rontani","year":"2000","journal-title":"Cell Microbiol"},{"issue":"45","key":"10.1016\/j.vaccine.2005.03.022_bib10","doi-asserted-by":"crossref","first-page":"15737","DOI":"10.1021\/bi981436i","article-title":"Characterization of membrane translocation by anthrax protective antigen","volume":"37","author":"Wesche","year":"1998","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.vaccine.2005.03.022_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1086\/338448","article-title":"Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol","volume":"185","author":"Cao","year":"2002","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2005.03.022_bib12","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1073\/pnas.97.14.8027","article-title":"Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity","volume":"97","author":"Lu","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.vaccine.2005.03.022_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/IAI.66.2.615-619.1998","article-title":"Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin","volume":"66","author":"Ballard","year":"1998","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2005.03.022_bib14","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1073\/pnas.1131930100","article-title":"A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen","volume":"100","author":"Kushner","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"10.1016\/j.vaccine.2005.03.022_bib15","doi-asserted-by":"crossref","first-page":"12059","DOI":"10.1073\/pnas.94.22.12059","article-title":"Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120\u2013anthrax toxin fusion protein","volume":"94","author":"Goletz","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"10.1016\/j.vaccine.2005.03.022_bib16","doi-asserted-by":"crossref","first-page":"12531","DOI":"10.1073\/pnas.93.22.12531","article-title":"Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo","volume":"93","author":"Ballard","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.vaccine.2005.03.022_bib17","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1128\/IAI.67.7.3290-3296.1999","article-title":"Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity","volume":"67","author":"Doling","year":"1999","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2005.03.022_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00109-002-0337-3","article-title":"CD4(+) T helper cells and the role they play in viral control","volume":"80","author":"Norris","year":"2002","journal-title":"J Mol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2005.03.022_bib19","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.4049\/jimmunol.172.5.2834","article-title":"CD4 T cell-dependent CD8 T cell maturation","volume":"172","author":"Khanolkar","year":"2004","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2005.03.022_bib20","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1128\/JVI.73.8.6715-6720.1999","article-title":"Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection","volume":"73","author":"Kalams","year":"1999","journal-title":"J Virol"},{"issue":"5342","key":"10.1016\/j.vaccine.2005.03.022_bib21","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1126\/science.278.5342.1447","article-title":"Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia","volume":"278","author":"Rosenberg","year":"1997","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.vaccine.2005.03.022_bib22","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/JVI.70.2.1072-1079.1996","article-title":"CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge","volume":"70","author":"von Herrath","year":"1996","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2005.03.022_bib23","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.4049\/jimmunol.147.12.4069","article-title":"In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help","volume":"147","author":"Fayolle","year":"1991","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2005.03.022_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0167-5699(00)01636-4","article-title":"Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40","volume":"21","author":"Walker","year":"2000","journal-title":"Immunol Today"},{"issue":"12","key":"10.1016\/j.vaccine.2005.03.022_bib25","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1147","article-title":"Therapeutic dendritic-cell vaccine for chronic HIV-1 infection","volume":"10","author":"Lu","year":"2004","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.vaccine.2005.03.022_bib26","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/374786","article-title":"T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy","volume":"187","author":"Hunt","year":"2003","journal-title":"J Infect Dis"},{"issue":"20","key":"10.1016\/j.vaccine.2005.03.022_bib27","doi-asserted-by":"crossref","first-page":"9771","DOI":"10.1128\/JVI.75.20.9771-9779.2001","article-title":"Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones","volume":"75","author":"Norris","year":"2001","journal-title":"J Virol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2005.03.022_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0022-1759(03)00265-5","article-title":"Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation","volume":"281","author":"Betts","year":"2003","journal-title":"J Immunol Methods"},{"issue":"13","key":"10.1016\/j.vaccine.2005.03.022_bib29","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1089\/088922201750461311","article-title":"Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay","volume":"17","author":"Sarr","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"10.1016\/j.vaccine.2005.03.022_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nri819","article-title":"T lymphocytes: all roads lead to death","volume":"2","author":"Barry","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"6831","key":"10.1016\/j.vaccine.2005.03.022_bib31","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/35073658","article-title":"Cellular immune responses to HIV","volume":"410","author":"McMichael","year":"2001","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.vaccine.2005.03.022_bib32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm0703-861","article-title":"Immunopathogenesis and immunotherapy in AIDS virus infections","volume":"9","author":"Letvin","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.022_bib33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00126334-200203010-00005","article-title":"Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A","volume":"29","author":"Gupta","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.vaccine.2005.03.022_bib34","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1128\/JVI.72.2.1552-1576.1998","article-title":"Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines","volume":"72","author":"Connor","year":"1998","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2005.03.022_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1399-0039.2004.00270.x","article-title":"HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting","volume":"64","author":"Paris","year":"2004","journal-title":"Tissue Antigens"},{"issue":"4","key":"10.1016\/j.vaccine.2005.03.022_bib36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/422258","article-title":"Safety and immunogenicity of an HIV subtype B and E prime\u2013boost vaccine combination in HIV-negative Thai adults","volume":"190","author":"Nitayaphan","year":"2004","journal-title":"J Infect Dis"},{"issue":"5560","key":"10.1016\/j.vaccine.2005.03.022_bib37","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1126\/science.295.5560.1616","article-title":"Disappointing data scuttle plans for large-scale AIDS vaccine trial","volume":"295","author":"Cohen","year":"2002","journal-title":"Science"},{"issue":"5656","key":"10.1016\/j.vaccine.2005.03.022_bib38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.1094620","article-title":"Public health. A sound rationale needed for phase III HIV-1 vaccine trials","volume":"303","author":"Burton","year":"2004","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05004007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X05004007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T23:07:37Z","timestamp":1706137657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X05004007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":38,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0264410X05004007"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}